Consultation | Global Scientific Panel on AMR and TB | Deadline 8 April 2024
In September 2024, the United Nations General Assembly will host a High-Level Meeting on Antimicrobial Resistance (UNHLM on AMR). This meeting follows a UNHLM on Tuberculosis (TB) in 2023.

Both AMR and TB are major global public health threats. The two agendas are closely intertwined, with drug-resistant TB a significant component of the AMR burden globally. Many of the drivers of DR-TB are common with the broader drivers of the AMR crisis. A successful UNHLM on AMR, which sees governments commit to concrete, cross-government action to address these drivers,  is therefore critical to meeting existing commitments to end TB and deliver on the broader Sustainable Development Goal agenda.

To support the coordinated and meaningful engagement of TB academics, researchers and healthcare workers in the UNHLM on AMR, a global panel of scientific experts from around the world is working to develop a white paper and aligned set of recommendations. Due to the broader focus of the UNHLM on AMR, the panel is focusing its efforts on intersections between the TB and AMR agendas, rather than steps needed to tackle TB or DR-TB alone.

The panel is inviting input from colleagues to ensure the final white paper reflects the expertise and priorities of the broader TB scientific community. We would welcome your expert input and advice!

To find out more about the panel and the priorities identified thus far, click here. 
To provide feedback and input, please fill out the below questionnaire by COB 8 April 2024.
Sign in to Google to save your progress. Learn more
First name
Surname
Institutional Affiliation
What is your email address?
What country are you based in? 
Which of the following best describes your profession?
Prevention has been identified as a key area for action. What evidence-informed steps should governments take to prevent the emergence of AMR, including DR-TB?  

Existing priority actions include: increased access to vaccines, strengthened WASH, improved infection prevention and control in healthcare settings, action on One Health. 
 *
Surveillance and laboratory infrastructures have been identified as a key area for action. What evidence-informed steps should governments take to improve the surveillance and diagnosis of AMR, including DR-TB?  

Existing priority actions include: integrated surveillance strategies, strengthened surveillance systems (passive and, where needed, periodic nationally representative surveys), integrated diagnostic strategies, strengthened diagnostic systems, increased access to genotypic and phenotypic DST, improved engagement of private and informal providers. 
 *
Increased access to quality treatment has been identified as a key area for action. What evidence-informed steps should governments take to improve access to quality antibiotic-based treatments, including for DR-TB? 

Existing priority actions include: reducing inappropriate prescription and over-the-counter sales of antibiotics (in particular Watch and Reserve antibiotics), improved engagement of the private and informal sector providers, strengthened procurement and quality assurance to increase access to most effective treatments while reducing risk of inappropriate, sub-standard and interrupted treatment. 
 *
Research and development has been identified as a key area for action. What evidence-informed steps should governments take to support research and development for AMR, including for DR-TB? 

Existing priority actions include: increased investment in needs-driven research including on: mechanisms of resistance, new vaccines, point-of-care diagnostics, rapid DST for novel antimicrobials, new antimicrobials and other treatments, social and behavioural research; ensuring equitable access to new tools through commitment to affordability, equity and right to science.
 *
Community engagement has been identified as a key area for action. What evidence-informed steps should governments take to strengthen community engagement to tackle AMR,  including for DR-TB? 

Existing priority actions include: action to increase public awareness of infectious diseases and AMR, active engagement and support of affected community to support demand generation. 
 *
Are there any priority areas for action that have not been identified above? 

Please note the focus on areas of intersection between efforts to tackle TB specifically and broader efforts to address AMR as a whole.  
 *
Are there any peer reviewed publications and/or case studies that you think the panel should reference in the final white paper?  

If so, please share references and/or links below. 
 *
Do you consent to further contact from us?

If so, we will keep you updated on the panel's work as well as opportunities to engage in national and global advocacy for the panel's recommendations. 
Clear selection
Submit
Clear form
Never submit passwords through Google Forms.
This form was created inside of CGH. Report Abuse
Google Forms